



BioSyent Inc.  
**Q2/H1 2025 Results**  
AUGUST 21, 2025

PRESENTED BY: RENÉ GOEHRUM  
PRESIDENT AND CEO



# DISCLAIMER

This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for BioSynt Inc., business and operational results.

By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to obtain governmental regulatory approvals, product recalls, competition from similar products and other factors including those risks and uncertainties identified above.

BioSynt Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.

All values in CAD unless otherwise indicated.







RepaGyn®

Cathejell®

*inofolic*® MD



<sup>c</sup>Tibella®

Tibelia Global




**Proktis-M**®

**Combogesic**® MD




# Sales, EBITDA and NIAT

## Quarter ended June 30<sup>th</sup> (Q2)



# Sales, EBITDA and NIAT

## First half ended June 30<sup>th</sup> (H1)




# Q2/H1 2025 Sales Summary (\$)

	Q2'25 Sales (\$)	Q2 '25 vs. Q2 '24 (%)	H1'25 Sales (\$)	H1 '25 vs. H1 '24 (%)
<b>Canadian Pharma (\$)</b>	<b>\$9,327k</b>	<b>+9%</b>	<b>\$18,487k</b>	<b>+15%</b>
Cathejell®		+1%		+8%
Combogesic®		-22%		-26%
FeraMAX® Pd		+10%		+14%
Gelclair®		-83%		-40%
Inofolic®		-9%		+94%
RepaGyn®		-13%		-2%
Tibella® (Canada)		+28%		+39%
<b>International Pharma (\$)</b>	<b>\$446k</b>	<b>+183%</b>	<b>\$1,981k</b>	<b>+1160%</b>
<b>Legacy (\$)</b>	<b>\$406k</b>	<b>+61%</b>	<b>\$690k</b>	<b>+57%</b>
<b>Total Company (\$)</b>	<b>\$10,179k</b>	<b>+14%</b>	<b>\$21,158k</b>	<b>+27%</b>

# Fully Diluted Earnings per Share (TTM)

**60** Consecutive  
Profitable Quarters  
to Q2 2025



# 2025 YTD Highlights



## Tibelia Global

- H1 2025: First Tibelia® Global shipments made by BioSynt: ~\$1.3 million in incremental revenue
  - Further orders planned for shipping H2 2025
- Mar/Jun 2025: Paid quarterly dividends of \$0.05/share (+11% increase vs. 2024)
- Aug 2025: Q3 2025 Dividend of \$0.05/share declared
- Apr 2025: FeraMAX® named #1 recommended iron supplement in Canada for **tenth** consecutive year
- YTD 2025: 19,500 shares repurchased and cancelled under NCIB





# Trade and Tariffs

---

## Unknowns Remain:

- USA-Canada Tariffs / Counter-Tariffs
- Impact on Canadian Consumers
- Impact on Canadian Economy



# FeraMAX<sup>®</sup>



- Most recommended iron supplement in Canada - pharmacists and physicians - **10** consecutive years<sup>(1)</sup>
- Continued innovation and expansion of FeraMAX<sup>®</sup> product line for iron health

*(1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2025 Survey on OTC Counselling and Recommendations*



## FeraMAX<sup>®</sup> LifeCycle Strategy

- Expanding leadership of FeraMAX<sup>®</sup> brand in Canada:

### “Iron health for life”

- FeraMAX<sup>®</sup> Pd platform introduced in October 2020
  - Patented delivery system based on Polydextrose Iron Complex (PDIC)



- FeraMAX<sup>®</sup> Pd Therapeutic 150 launched Nov 2020
- FeraMAX<sup>®</sup> Pd Powder 15 launched Oct 2021
- FeraMAX<sup>®</sup> Pd Maintenance 45 launched Mar 2023
- Development of additional FeraMAX<sup>®</sup> Pd Products

# Innovations, Product Launches and Acquisitions



Tibella®

Jul 2020



FeraMAX® Pd

Oct 2020



FeraMAX® Pd Therapeutic 150

Nov 2020



Combogesic®

Dec 2020



FeraMAX® Pd Powder 15

Oct 2021



FeraMAX® Pd Maintenance 45

Mar 2023



Inofolic®

Aug 2023



Gelclair®

Nov 2023



Tibelia® Global

Sep 2024



New endocrinology asset

TBD




FeraMAX® Pd products in development

TBD






# 15 Years of Profitable Growth (and Counting!)



# Cash Balance & Return on Equity (“RoE”)

Trailing Twelve Months ended June 30th




- Zero Debt
- TTM Cash from Operations of **\$12.0M**
- TTM NCIB share buybacks: **\$4.0 M**
- TTM Dividends of **\$2.2M**
- Jun 30/25 Working Capital of **\$25.6M**
- Execution of strategy drives TTM RoE of **23%**



# Capital Allocation linked to Strategy

First use of capital is to generate revenue/profit growth & portfolio diversification.



- 7 new product launches in Canada since July 2020
- Tibelia® / Tibella® (tibolone) Global Acquisition in Sept 2024

# Stock Information

As at August 19, 2025

Exchange & Trading Symbol	TSXV: RX
Aug 19, 2025 Closing Stock Price (CAD) (TSXV):	\$11.35
52 Week Hi/Low (TSXV):	\$12.13 / \$9.20
Issued Common Shares:	11,474,931
Treasury – RSU Shares in Trust	<u>(214,137)</u>
Outstanding Common Shares:	11,260,794
Options Outstanding	105,471
RSUs Outstanding	<u>209,771</u>
Fully Diluted Common Shares:	11,576,036
P/E Ratio :	15.91
EV/EBITDA :	9.46





- ✓ PROFITABLE.
- ✓ WELL CAPITALIZED.
- ✓ GROWTH ASSETS.
- ✓ FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN.

